Changes afoot at GSK; The first vic­tim of IRA?; As work halts, fam­i­lies be­hind gene ther­a­py seek con­trol; and more

Wel­come back to End­points Week­ly, your re­view of the week’s top bio­phar­ma head­lines. Want this in your in­box every Sat­ur­day morn­ing? Cur­rent End­points read­ers can vis­it their read­er pro­file to add End­points Week­ly. New to End­points? Sign up here.

The vac­cine R&D rev­o­lu­tion has gone glob­al. How will the lessons from Covid-19 re­shape the way we study, test, pro­duce and dis­trib­ute vac­cines around the world? Join me on Wednes­day for a pan­el dis­cus­sion. You can sign up at no cost here.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER